teaser mc health tech project
TRANSCRIPT
TEASERINVESTMENT OPPORTUNITY
MCHT: A global medical device company
Confidential – MC HEALTH TECH – Contact: [email protected] – May 2013
General overview of MC Health Tech
MC Health Tech Business Description
• Global company engaged in the research, development, and marketing of medical devices that standardize physical therapy.
• We own a novel proprietary technology (Patent Applications PCT/EP2011/052314) that represents a leap change on reproducibility and
efficacy of physical therapy, supported by solid clinical evidence.
• Two products in the market, LIPODREN and PHYSIUM, that relieve chronic and acute pain, relax stiffness, release tissue adhesions, improve
fibrosis of scar tissue, and lymphatic circulation.
• LIPODREN is a baseline robot for the aesthetic market (cellulite, oedema, and lymphatic retention).
• PHYSIUM is a sophisticated device that allows the user to have full control of parameters and that in addition to same specifications of
LIPODREN, is under development for the treatment of high prevalent chronic disorders, such as:
• Musculoskeletal system: neck pain, low back pain, myalgia; with high prevalence (14-19% of total population; 1.35% of total US health
care expenditures; estimated market of $ 51,6 billion in OECD countries).
• Disorders associated with neuropathies: spasticity, neuralgia.
• Postural fibrosis: scar pain, adhesions, thickening.
• 2 MM € sales in Spain; we have secured worldwide rights.
• 16.000 patients have been treated in usual clinical practice; in 9.400 monitored patients, strong efficacy in retrospective analysis and
prospective clinical studies, excellent safety profile (2,2 % minor nor AE) and outstanding efficacy (retrospective analysis of patients and
prospective POC clinical studies).
Confidential – MC HEALTH TECH – Contact: [email protected] – May 2013 2
General overview of MC Health Tech
MC Health Tech technology and products
Innovative set of protocols, SD Method & Software.
This technology allows to:
• Standardize manual therapy with high reproducibility.
• Conduct clinical research.
• Prevent injuries and increase productivity among
physiotherapists.
• Develop treatments for high prevalence unmet medical needs
(chronic neck and back pain, etc.).
Confidential – MC HEALTH TECH – Contact: [email protected] – May 2013 3
Proof of concept in 20 chronic neck pain patients
Hard to treat patient population.
Did not respond to standard therapy and other treatments:
• 100% of patients resolve pain after 4 visits.
• 95% of patients motility goes back to normal.
COSMOPROF 2013 (Bologna, It)
MCHT attended the largest professional fair in Europe.
• Distributors in Italy, Japan, Korea, Japan interested in MCHT
booth.
• Lipodren extremely well received:
• “...unique product...”
• “fulfills unmet need...”
SD evaluation method
Proprietary software
Accessories
LIPODREN
Aesthetic market
Volumen reduction,
C-section
and cellulite
PHYSIUM
Physical therapist market
Myofascial
and joint pain
Similar results in low
back pain patients
General overview of MC Health Tech
Project plan & business model
• Manufacture and sell worldwide our devices and accessories through
distributors to:
• Physiotherapists and rehabilitation physicians.
• Aesthetic market professionals.
• Demonstrate clinical efficacy and safety, and obtain regulatory
approval from FDA, EMA.
• Long term revenue will come from device maintenance, accessories,
spare parts, and new software.
• Target market includes over 1 million physical therapist centres, and
1,5M of beauty centres in OECD countries.
• PHYSIUM annual sales projections in OECD market are of €280M
from the 8th year (3% accumulated share), and LIPODREN are of
€275M from the 10th year (3% accumulated share).
Confidential – MC HEALTH TECH – Contact: [email protected] – May 2013 4
Key factors of investment
• Investment needs: 4.000.000 € (allocation: commercial activities:
1.300.000 €; regulatory & clinical trials: 1.100.000; overheads for first
2 years: 1.600.000 €).
• Investor profile: preferably with experience in either medical or
aesthetic markets.
Sales, EBITDA and gross profit (%) forecast
Experienced team
• Strong & experienced management team covering major areas for an
international business project.
Francesc Trias, CEO
Xavier Buxareu, MD, COO
Carme Carré, PhD, MD
• Supported by Scientific Advisory & Directors Boards:
Joaquim Trias, PhD. Director
Mark Stultz, PT